arachidonate ͉ linoleate ͉ hypertension ͉ atherosclerosis
12͞15-Lipoxygenase (LOX) activity is elevated in vascular diseases
arachidonate ͉ linoleate ͉ hypertension ͉ atherosclerosis N itric oxide ( ⅐ NO) is a central mediator of vascular tone, with strict control of ⅐ NO essential for blood pressure regulation (1, 2) . Reaction with oxyhemoglobin (oxyHb) has generally been viewed the major fate of vascular ⅐ NO; however, recent work has shown that hemoglobin sequestration, combined with flow, decreases the rate of ⅐ NO reaction with oxyHb, rendering it less effective as an ⅐ NO scavenger (3) (4) (5) . In vascular disease, accelerated ⅐ NO loss is often seen (6) (7) (8) . In hypertension, a role for superoxide (O 2 . ) has been found; however, this is only responsible for a proportion of ⅐ NO removal, because O 2 . scavengers incompletely normalize blood pressure (8) . Finally, the biological half-life of ⅐ NO under oxyHb-free conditions (0.1-3 sec) is shorter than expected rates of ⅐ NO oxidation (9, 10) . These observations suggest that cell-dependent ⅐ NO scavenging occurs under both physiological and pathophysiological conditions. Vascular ⅐ NO consumption may occur via reaction with free radicals formed during turnover of enzymes that are upregulated during disease. For example, we have shown that 15-lipoxygenases (LOX) and prostaglandin H synthase (PGHS) catalytically consume ⅐ NO (11, 12) . A central role for oxymyoglobin in regulating coronary blood flow and cardiac contractility has been recently shown (13) . Finally, the heme peroxidases, myeloperoxidase (MPO), lactoperoxidase (LPO), and eosinophil peroxidase (EPO) scavenge ⅐ NO as a reducing peroxidase substrate (14) .
LOXs are non-heme iron-containing enzymes that catalyze the oxidation of unsaturated fatty acids (15, 16 (18) . 15-and 12͞15-LOXs play a central role in vascular disease, because (i) 15-LOX mRNA, protein, and lipid products are found in atheroma, (ii) inhibition of 15-LOX prevents atherosclerosis in rabbits, and (iii) functional inactivation of the 12͞15-LOX gene slows down aortic lipid deposition in apo E-deficient mice, and inhibits streptozotocin-induced diabetes (19) (20) (21) (22) (23) (24) (25) . Furthermore, in vivo, 12͞15-LOX expression is required for neointimal thickening in ballooninjured rat aortae (26, 27) . 12͞15-LOX is elevated in smooth muscle of angiotensin (ang) II-dependent hypertensive rats (28) (29) (30) . Also, ang II up-regulates 12͞15-LOX in mouse macrophages and porcine smooth muscle in vitro via the AT 1 receptor (31, 32) . Inhibition of 12͞15-LOX by nonspecific inhibitors reduces blood pressure in hypertensive rats, and ang II-induced smooth muscle hypertrophy (33) (34) (35) (36) . The mechanism(s) by which 12͞15-LOX contributes to vascular tone and smooth muscle proliferation is unclear.
Previously, purified rabbit and human 15-LOX was found to catalytically consume ⅐ NO and inhibit soluble guanylate cyclase (sGC) activation in vitro (11) . In this study, the concept of tissue regulation of ⅐ NO by LOX is extended to 12͞15-LOX, and we show that activity of this isoform in primary monocytes is sufficient to prevent sGC activation by 2 M ⅐ NO. These studies demonstrate a novel mechanism by which cellular LOXs can contribute to vascular disease, independently of their lipid product bioactivity, namely by attenuating the vasodilatory and antiinflammatory actions of ⅐ NO.
sham Pharmacia. LA was from Nu Chek Prep (Elysian, MN). Lymphoprep was from Nycomed (Oslo). Cell culture media was from GIBCO Life Technologies. Unless otherwise stated, other reagents were from Sigma.
Generation of 12͞15-LOX-Transfected Rat Smooth Muscle Cells. Rat smooth muscle A10 cells from American Type Culture Collection, cultured in DMEM, 15% (vol͞vol) FCS, 100 g͞ml penicillin, 100 units͞ml streptomycin, and 2 mM glutamine, were cotransfected with plasmids encoding mouse 12͞15-LOX cDNA (pcDNAm12LO, a gift from Dr. C. Funk, University of Pennsylvania, Philadelphia) and pPUR [selection vector that confers puromycin resistance (25:1 ratio); Promega] using lipotaxi (Boehringer Mannheim). The empty vector pcDNA1 (Invitrogen) without the 12͞15-LOX cDNA insert was separately cotransfected with pPUR. About 6 h posttransfection, cells were placed in recovery medium containing 1% (vol͞vol) FCS and fed the next day with complete medium. Cells were split 1:12, 48 h post transfection, and then 24 h later selection initiated by using 2.0 g͞ml puromycin. After resistant colonies developed (3-4 weeks), clones were picked by using cloning rings and expanded. Clones were checked for 12͞15-LOX overexpression by Western blotting and 12(S)HETE generation. Stable transfectants were maintained in complete medium with 1 g͞ml puromycin.
Isolation of Porcine Monocytes. Porcine monocytes were isolated as described (37) . Briefly, whole blood was diluted into PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , pH 7.4) at 10:1, blood:PBS (vol͞vol) containing 10 units͞ml heparin and 0.5 mM EDTA then mixed 1:1 (vol͞vol) with PBS, 0.8% (wt͞vol) trisodium citrate, and 2% (wt͞vol) dextran T-70 (pH 7.4) and left to sediment for 60 min. The upper plasma layer was underlaid with ice-cold Lymphoprep [2:1, plasma:Lymphoprep (vol͞vol)]. This was centrifuged (800 ϫ g, 20 min, 4°C) before harvesting the interface and diluting 1:1 (vol͞vol) with PBS, 0.4% (wt͞vol) trisodium citrate (pH 7.4; PBS͞citrate). Cells were pelletted (400 ϫ g, 10 min, 4°C) and then washed (recentrifuged at 400 ϫ g, 10 min, 4°C, followed by resuspension in PBS͞citrate) four times. Cells were seeded at 10 8 per 75 cm 2 flask in Medium 199 with 15% (vol͞vol) newborn calf serum, 2 mM L-glutamine, 100 g͞ml penicillin, 100 units͞ml streptomycin, and incubated at 37°C, 5% CO 2 for 2 h. Cells were washed twice with sterile PBS (wt͞vol). After a further 1-h incubation in medium, cells were washed four times, then incubated 12-16 h in medium.
Western Blotting of LOX. Immunoblotting was performed as described (38) . Briefly, porcine monocytes or A10 cells in PBS containing protease inhibitors were assayed for protein (39) , then diluted into SDS-sample buffer [250 mM Tris, 40% (vol͞vol) glycerol, pH 6.75, 8% (wt͞vol) SDS, 20% (vol͞vol) 2-mercaptoethanol, 0.005% (wt͞vol) bromophenol blue] and boiled for 10 min. Samples (15-30 g protein) were separated on a 10% SDS-polyacrylamide gel, and transferred onto a nitrocellulose membrane. Membranes were probed with polyclonal anti-rabbit reticulocyte 15-LOX antibody (1:1,500) and visualized by using enhanced chemiluminescence (Amersham Pharmacia) after incubation with a horseradish peroxidaseconjugated anti-guinea pig secondary antibody. Porcine monocyte cDNA was amplified by touchdown PCR, with an initial denaturation step at 94°C for 5 min, followed by 40 cycles of 1 min at 94°C, 2 min starting at 69°C (with a 0.5°C drop in temperature between cycles), and 72°C for 2 min, with a final extension of 72°C for 5 min. PCR products were then amplified with a second round of PCR of 94°C for 5 min followed by 30 cycles of 94°C for 1 min, 53°C for 2 min, 72°C for 2 min, and a final step of 72°C for 5 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control: forward primer, 5Ј-CCCATCACCATCTTCCAGGAG-3Ј (position 211-231); reverse primer, 5Ј-GTTGTCATGGATGACCTTGGC-3Ј (position 475-495); with conditions as for second round PCR outlined above. PCR products were visualized on a 1.5% (wt͞vol) agarose gel treated with ethidium bromide (2.0 g͞g agarose), using a Bio-Rad GelDoc UV illuminator.
RNA Extraction and Reverse Transcriptase (RT)-PCR of
RIA of LOX Products in Transfected A10 Cells. Cells were incubated in serum-free medium overnight, then in fresh serum-free medium for 30 min at 37°C. Cells and supernatants were extracted as described (33, 40) . First, cell pellets were deacylated by treatment with 1.5 ml 0.2 M NaOH in methanol, 50 M n-propyl gallate under N 2 for 45 min. The solution was then diluted to 15% methanol and extracted, and LOX products in the cell pellets and supernatants were quantified by using a specific RIA (41) .
Measurement of ⅐ NO Consumption. Anaerobic solutions of ⅐ NO (1.9 mM) were prepared by bubbling ⅐ NO gas through N 2 -saturated, deionized water. Any ⅐ NO 2 was removed by bubbling ⅐ NO through 1 M NaOH. ⅐ NO was measured by using a selective ⅐ NO sensor (IsoNo, WPI, Sarasota, FL). Electrode calibration was performed by measuring ⅐ NO release from S-nitrosoacetylpenacillamine (SNAP) as in the electrode manual. When ⅐ NO loss was not linear, rates were determined as first order rate constants (k obs ) calculated by determining the slope of ln[ ⅐ NO] versus time. For all k obs determined, the square of the Pearson product moment correlation coefficient (r) for the slope of the replotted data were always greater than 0.9, confirming that the reaction followed first order kinetics. For all ⅐ NO consumption rates, data are the means Ϯ SD (n ϭ 3).
For measurement of ⅐ NO consumption by porcine 12͞15-LOX, 3.8 M ⅐ NO was added to 100 mM potassium phosphate buffer (pH 7.4), 100 M diethylenetriaminepentaacetic acid (DTPA), 0.2% (wt͞vol) sodium cholate containing 500 M LA or AA at 37°C with stirring. LOX (2.8 milliunits) was added 1 min before ⅐ NO (1 unit ϭ 1 mol͞min substrate oxidized). For measurement of ⅐ NO uptake by A10 cells, confluent monolayers were trypsinized, washed three times in ice-cold PBS (pH 7.4), counted, and kept on ice in PBS. For assay, 10 6 cells were added to 0.5 ml Krebs buffer (50 mM Hepes, 100 mM NaCl, 5 mM KCl, 1 mM NaH 2 PO 4 ⅐ 2H 2 O, 1 mM CaCl 2 , 2 mM glucose, 1 mM MgCl 2 , pH 7.4) containing 100 M DTPA in the ⅐ NO electrode chamber at 37°C with stirring. ⅐ NO (1.9 M) was then added and rates of decay monitored with͞without additions of 500 M LA. Porcine monocytes were harvested by trypsinization and gentle scraping before washing in PBS and finally resuspending in Krebs buffer (pH 7.4). Cells (0.5 ϫ 10 6 ) in 0.5 ml Krebs buffer containing 100 M DTPA and 10 M diphenylene iodonium (DPI) were placed in the chamber of the ⅐ NO electrode at 37°C with stirring. In some experiments, cells were preincubated for 10 min with 10 M indomethacin or 200 M eicosatetraynoic acid (ETYA). ⅐ NO (1.9 M) was added, and rates of ⅐ NO decay monitored with͞without additions of 150 M AA or LA.
Conjugated Diene Generation by 12͞15-LOX. Conjugated diene was measured spectrophotometrically at 235 nm ( 235 ϭ 28 mM Ϫ1 ⅐cm
Ϫ1
). Seven milliunits of 12͞15-LOX was added to 1 ml of 100 mM phosphate buffer (pH 7.4, 37°C) containing 100 M DTPA, 500 M LA, and 0.2% (wt͞vol) sodium cholate. Where LOX was added, 3.8 M ⅐ NO was added at the same time.
Reverse-Phase HPLC of HPETEs. Sequential additions (12 total) of 3.8 M ⅐ NO were made to 1 ml phosphate buffer (100 mM, pH 7.4) containing 100 M AA, 100 M DTPA, and 0.2% (wt͞vol) sodium cholate at 37°C with stirring. Following each ⅐ NO addition, 2.8 milliunits of 12͞15-LOX was added and ⅐ NO consumption monitored. As ⅐ NO decay slowed because of selfinactivation of 12͞15-LOX, more ⅐ NO and 12͞15-LOX was added (total 12͞15-LOX per sample was 28 milliunits). Control samples were generated by sequential additions of 12͞15-LOX to 1 ml of phosphate buffer (100 mM, pH 7. cGMP Determination. Porcine monocytes harvested by trypsinization and scraping were washed in PBS then resuspended in Krebs buffer (pH 7.4). Cells (2 ϫ 10 6 ) in 0.5 ml Krebs buffer containing 100 M DTPA, 10 M DPI, and 1 mM isobutylmethylxanthine (IBMX) were placed in the chamber of the ⅐ NO electrode at 37°C with stirring. ⅐ NO (1.9 M) was added, followed by 150 M LA or 3 M oxyHb. Samples were incubated for 5 min, then 100 l was removed and added to 195 l of ice-cold ethanol for (cGMP) analysis, using a commercial RIA according to the manufacturer's instructions (Amersham Pharmacia).
Results

Expression of 12͞15-LOX in Porcine Monocytes.
To examine for ⅐ NO uptake by 12͞15-LOX in primary vascular cells, porcine monocytes were chosen because they constitutively express this isoform (42, 43) . To confirm LOX expression, Western blotting and RT-PCR were carried out on the cells. As shown, immunoreactivity toward an anti-rabbit 15-LOX antibody was found for both isolated porcine monocytes and the commercially available porcine 12͞15-LOX (Fig. 1A) . Further evidence for expression of 12͞15-LOX in porcine monocytes is shown by detection of a PCR product of the expected size (333 bp) for porcine 12͞15-LOX in cDNA derived from total porcine monocyte RNA (ref. 32 ; Fig. 1B ). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers used in parallel to ensure cDNA integrity also yielded a product of the expected size (284 bp; Fig. 1C ).
Loss of ⅐ NO in the Electrode. ⅐ NO (1-4 M) decay in Krebs buffer or PBS at 37°C followed first order kinetics with a k obs of 6.65 Ϯ 0.25 ϫ 10 Ϫ3 sec
Ϫ1
. Whereas ⅐ NO decay through reaction with oxygen is second order, ⅐ NO loss herein was primarily through diffusion into the gas phase and oxidation by the electrode. k obs was used to calculate background ⅐ NO losses, which were subtracted from enzyme-or cell-dependent ⅐ NO uptake rates. Fig. 2B ). However, preincubation of monocytes with ETYA for 10 min fully blocked both LA-and AA-stimulated ⅐ NO consumption (Fig. 2B) . Omission of indomethacin resulted in Ϸ20% faster rates of ⅐ NO consumption when AA was used as substrate, but had no effect on LAstimulated rates (data not shown). These data suggest that porcine monocytes consume biologically significant quantities of ⅐ NO via 12͞15-LOX catalysis.
Consumption of ⅐ NO Prevents Activation of Porcine Monocyte sGC.
To determine whether unsaturated fatty acid-stimulated consumption of ⅐ NO can modulate ⅐ NO bioactivity, cGMP generation was determined following a 5 min incubation of monocytes with ⅐ NO with͞without LA. The nonselective phosphodiesterase inhibitor, isobutylmethylxanthine (IBMX), was included to minimize cGMP hydrolysis. Following incubation with 1.9 M ⅐ NO, significant elevations in monocyte cGMP were found. When 150 M LA was added immediately following ⅐ NO, cGMP generation was significantly suppressed, whereas LA alone did not alter basal cGMP synthesis (Fig. 2C) . Addition of 3 M oxyhemoglobin to scavenge ⅐ NO fully blocked ⅐ NO activation of sGC.
Consumption of ⅐ NO by 12͞15-LOX-Transfected Smooth Muscle Cells.
Because ETYA used to inhibit porcine monocyte LOX activity is not a highly specific LOX inhibitor, rat smooth muscle cells (A10) overexpressing murine 12͞15-LOX were generated. To confirm the presence of active 12͞15-LOX, 12-HETE synthesis was measured and found to be Ϸ6-fold greater in 12͞15-LOXcontaining cells than null-transfected controls (Fig. 3B) . Also, Western blotting of A10 lysates demonstrated LOX protein only in 12͞15-LOX-transfected cells (Fig. 3C) . The presence of A10 cells (2 ϫ 10 6 ml Ϫ1 ) in the sample chamber of the ⅐ NO electrode resulted in slightly increased ⅐ NO decay rates (k obs ϭ 8.03 Ϯ 1.79 ϫ 10 Ϫ3 sec
Ϫ1
; Fig. 3A ) over background, which were similar in both cell types. However, on addition of LA to 12͞15-LOXcontaining cells, the rate of ⅐ NO consumption increased significantly (0.22 Ϯ 0.08 nmol⅐min Ϫ1 ⅐10 6 cells Ϫ1 after background correction). In contrast, null-transfected A10 cells did not display LA-dependent ⅐ NO consumption (Fig. 3A) . These data confirm that cellular 12͞15-LOX consumes ⅐ NO in the presence of fatty-acid substrates.
Consumption of ⅐ NO by Porcine 12͞15-LOX. To examine the effect of ⅐ NO consumption on the catalytic activity of 12͞15-LOX, a purified porcine 12͞15-LOX was used (44) . In the absence of fatty acids, 12͞15-LOX did not increase rates of ⅐ NO decay (Fig.  4 A and B) . However, accelerated rates of ⅐ NO consumption were observed in the presence of 500 M LA or AA (2.50 Ϯ 0.83 nmoles⅐min Ϫ1 ⅐mg Ϫ1 or 3.72 Ϯ 0.70 nmoles⅐min Ϫ1 ⅐mg
, respectively; mean Ϯ SD, n ϭ 3; Fig. 4A ). ⅐ NO consumption required the presence of both 12͞15-LOX and unsaturated fatty acids (Fig. 4B) , indicating that 12͞15-LOX consumes ⅐ NO during dioxygenase turnover. To examine the effect of ⅐ NO on 12͞15-LOX activity, rates of LOX-catalyzed diene conjugation were determined in the presence and absence of ⅐ NO. As shown in Fig.  4D , ⅐ NO inhibited LOX activity by Ϸ20%. Analysis of LOX products by reverse phase HPLC confirmed ⅐ NO suppression of LOX (Fig. 4C) and also indicated that 12-HPETE remained the major product of LOX turnover in the presence of ⅐ NO.
Discussion
Porcine and murine 12͞15-LOX catalytically consumed ⅐ NO in the presence of unsaturated fatty acid substrates, with LAstimulated ⅐ NO removal preventing activation of sGC in primary porcine monocytes. Elevation of cGMP in monocytes and macrophages prevents chemotaxis, cytokine release, and IgG complex uptake (45) (46) (47) . Therefore, catalytic consumption of ⅐ NO by 12͞15-LOX will attenuate the multifaceted antiinflammatory properties of ⅐ NO. These findings establish 12͞15-LOX as a potential catalytic sink for ⅐ NO in vivo, similar to myoglobin, 15-LOX, PGHS-1, and myeloperoxidase (MPO) (11) (12) (13) (14) . They also reveal an additional mechanism for the prohypertensive and proatherogenic activity of 12͞15-LOX that is distinct from generation of bioactive lipid products.
12͞15-LOX expression is induced in macrophages and smooth muscle cells by ang II through the AT 1 receptor with several lines of evidence suggesting a role for this isoform in the pathogenesis of ang II-induced hypertension and neointima formation after balloon injury (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Mechanisms by which 12͞15-LOX contributes to vascular dysfunction have not been characterized, but could include (i) vasoconstrictive effects of HPETE͞HETEs, which occur at relatively high concentrations of 0.5-1 M (48, 49), and (ii) prevention of ⅐ NO signaling by catalytic ⅐ NO consumption as shown in this study.
15-LOXs, including rabbit, human, and soybean isoforms, catalytically consume ⅐ NO in the presence of unsaturated lipids through radical termination between ⅐ NO and an enzyme-bound lipid peroxyl radical (E red LOO⅐; ref. 11). The product of this reaction, an alkyl peroxynitrite (LOONO), then undergoes hydrolysis, forming the expected lipid hydroperoxide (LOOH; ref. 11). Consumption of ⅐ NO by 15-LOXs coincides with reversible suppression of turnover through formation of the inactive reduced enzyme (E red ), which requires reactivation through a rate-limiting step (11, 50) . The porcine 12͞15-LOX undergoes irreversible self-inactivation after 2-3 min of dioxygenase turnover; therefore, detailed mechanistic studies on this isoform were not possible. However, unsaturated fatty acidstimulated ⅐ NO consumption, suppression of dioxygenase activity, and a lack of changes in lipid product profile are identical to the interactions of ⅐ NO with 15-LOXs observed ( Fig. 4; , respectively) indicates that these pathways would cause similar rates of ⅐ NO consumption by monocytes when turning over at maximal rates. Their relative importance in controlling ⅐ NO bioactivity in vivo will therefore depend on their activities under inflammatory-activated conditions, and local concentrations of superoxide dismutase (SOD). Although the PGHS inhibitor indomethacin had no effect on LA-catalyzed ⅐ NO consumption by porcine monocytes, AA-stimulated rates were inhibited by 20%. This observation suggests that PGHS may also consume ⅐ NO in monocytes, although at lower rates.
A role for 12͞15-LOX in catalyzing ⅐ NO consumption by monocytes was indicated by substrate dependency, inhibition with ETYA, and the observations of LOX protein and mRNA expression ( Figs. 1 and 2 ). Further support was obtained by using 12͞15-LOX-transfected A10 smooth muscle cells, which also consumed ⅐ NO on addition of LA (Fig. 3) . Comparisons of 12͞15-LOX protein levels on Western blots indicated that porcine monocytes express higher levels of this enzyme than transfected A10 cells (data not shown). This difference in expression is reflected in the 75% lower rates of LA-stimulated ⅐ NO consumption by these cells.
Rates of LA-or AA-stimulated ⅐ NO consumption by porcine monocytes were considerably greater than documented rates of ⅐ NO generation by iNOS in cytokine-activated rat peritoneal macrophages or murine RAW264.7 macrophages (e.g., 0.1 and 0.2 nmol ⅐ min Ϫ1 ⅐ 10 6 cells Ϫ1 , respectively; refs. 54 and 55), indicating that LOX-dependent ⅐ NO consumption will have a significant impact on ⅐ NO bioactivity. In this study, LOX turn- over was initiated by exogenous addition of substrates, because acutely activating agonists for cellular 12͞15-or 15-LOX have not been identified (Fig. 2) . The presence of specific LOX products in early atherosclerotic lesions indicates that LOX catalysis occurs in vivo, although precise control mechanisms remain to be elucidated (19) (20) (21) . Herein, inclusion of the metal chelator DTPA prevents secondary nonenzymatic generation of additional lipid radicals. In vivo, where LOX-derived LOOH decomposes in advanced atheroma, the consumption of ⅐ NO by nonenzymatic lipid oxidation will further amplify rates of LOXdependent ⅐ NO removal.
In summary, we reveal that 12͞15-LOX catalytically consumes ⅐ NO and that this process impairs ⅐ NO signaling in primary porcine monocytes. Under basal conditions, ⅐ NO plays a central role in maintaining vascular homeostasis (56) (57) (58) (59) . Thus, stimulation of ⅐ NO consumption by monocytes will contribute to proatherogenic conditions by increasing leukocyte adhesion and margination. These findings have implications for our understanding of the role of LOX enzymes in the development of atherosclerosis and hypertension and reveal 12͞15-LOX as a potential catalytic sink for ⅐ NO in vivo.
